In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including Esperion’s recent regulatory approval in Japan for their drug NEXLETOL, which marks a significant milestone in their commercial expansion. This approval allows their partner, Otsuka Pharmaceuticals, to market the drug for hypercholesterolemia and familial hypercholesterolemia in Japan, one of the top global markets for cardiovascular prevention. The successful Phase 3 trial results in Japan, which showed significant LDL-C reduction, further support the drug’s potential.
Additionally, the inclusion of Esperion’s BDA in the updated 2025 European guidelines as the only new non-statin therapy recommended for LDL-C lowering and cardiovascular risk reduction strengthens the company’s market position. This endorsement by the European Society of Cardiology and the European Atherosclerosis Society validates the clinical benefits of BDA and supports its ongoing adoption and market access expansion across Europe. These developments, along with the potential for dual and triple combination therapies, contribute to a positive outlook for Esperion’s commercial strategy.